Investors should pay attention to the buying and selling patterns of company insiders, as these moves often indicate potential stock performance. On November 17, 2025, MOLINA ARTURO MD sold 2,712 shares of Protagonist Therapeutics Inc, (PTGX) valued at $229,896. At $84.77 per share, the insider’s holdings dropped to 81,180 shares, now worth around $7.31 million.
Meanwhile, Waddill William D. sold 12,000 shares for a total of over $979,480, at a price of $81.62 per share. Following this sale, Waddill’s holdings dropped to 5,130 shares. Interestingly, Waddill had previously added 12,000 shares to his account in a purchase valued at $804,480, buying at $67.04 per share.
Analyst Ratings
Protagonist Therapeutics Inc has attracted attention from several major analysts this year. Barclays initiated coverage on September 17, 2025, with an “Overweight” rating and raised the price target to $72. Leerink Partners also began coverage in mid-September with an “Outperform” rating. Citigroup started tracking the stock with a “Buy” rating as of June 17, 2025. Goldman Sachs previously initiated a “Neutral” rating on December 6, 2024.
Analyzing PTGX Stock Performance
Protagonist Therapeutics Inc [NASDAQ: PTGX] saw a small uptick of 0.23% in its last trading session, closing at $90.07. The stock reached a low of $89.50 and a high of $90.8499 during the session. Over the past five days, PTGX has gained approximately 5.80%, while its year-to-date performance shows an impressive 93.87% increase. The stock hit a 52-week high of $93.25 on October 10, 2025, and a low of $33.70 on February 25, 2025.
Support and Resistance
On the 24-hour chart, PTGX shows a support level at $89.43, with a potential drop to $88.79 if breached. Resistance lies at $90.78, with the next level at $91.49. The 14-day Relative Strength Index (RSI) is 72.32, indicating overbought conditions and suggesting cautious optimism among traders.
Short Interest Trends
Short interest in Protagonist Therapeutics Inc fell sharply on November 14, 2025, dropping by 0.73 million shares to 5.58 million. Compared with October 15, 2025, when short interest stood at 6.31 million shares, this represents a 13.07% decline. Short shares make up just 5.46% of the overall float, and the days-to-cover ratio has also decreased to 5.46, signaling a more positive market sentiment.
Major Shareholders
FactSet research shows analysts setting an average price target of $88 for PTGX over the next 12 months, slightly below the previous closing price of $89.86. Price targets range from $72 to $112, reflecting mixed expectations. Despite this, four analysts still rate the stock as a Buy at the end of 2025. On December 6, 2024, BMO Capital Markets initiated coverage with an “Outperform” rating and a price target of $62.
